Historical Valuation
Perspective Therapeutics Inc (CATX) is now in the Fair zone, suggesting that its current forward PS ratio of 350.46 is considered Fairly compared with the five-year average of -12.57. The fair price of Perspective Therapeutics Inc (CATX) is between 1.44 to 3.12 according to relative valuation methord.
Relative Value
Fair Zone
1.44-3.12
Current Price：2.84
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Perspective Therapeutics Inc (CATX) has a current Price-to-Book (P/B) ratio of 0.86. Compared to its 3-year average P/B ratio of 1.58 , the current P/B ratio is approximately -45.66% higher. Relative to its 5-year average P/B ratio of 1.80, the current P/B ratio is about -52.32% higher. Perspective Therapeutics Inc (CATX) has a Forward Free Cash Flow (FCF) yield of approximately -51.46%. Compared to its 3-year average FCF yield of -22.79%, the current FCF yield is approximately 125.81% lower. Relative to its 5-year average FCF yield of -17.24% , the current FCF yield is about 198.54% lower.
P/B
Median3y
1.58
Median5y
1.80
FCF Yield
Median3y
-22.79
Median5y
-17.24
Competitors Valuation Multiple
AI Analysis for CATX
The average P/S ratio for CATX competitors is 77.40, providing a benchmark for relative valuation. Perspective Therapeutics Inc Corp (CATX.A) exhibits a P/S ratio of 350.46, which is 352.78% above the industry average. Given its robust revenue growth of -43.36%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CATX
1Y
3Y
5Y
Market capitalization of CATX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CATX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CATX currently overvalued or undervalued?
Perspective Therapeutics Inc (CATX) is now in the Fair zone, suggesting that its current forward PS ratio of 350.46 is considered Fairly compared with the five-year average of -12.57. The fair price of Perspective Therapeutics Inc (CATX) is between 1.44 to 3.12 according to relative valuation methord.
What is Perspective Therapeutics Inc (CATX) fair value?
CATX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Perspective Therapeutics Inc (CATX) is between 1.44 to 3.12 according to relative valuation methord.
How does CATX's valuation metrics compare to the industry average?
The average P/S ratio for CATX's competitors is 77.40, providing a benchmark for relative valuation. Perspective Therapeutics Inc Corp (CATX) exhibits a P/S ratio of 350.46, which is 352.78% above the industry average. Given its robust revenue growth of -43.36%, this premium appears unsustainable.
What is the current P/B ratio for Perspective Therapeutics Inc (CATX) as of Jan 10 2026?
As of Jan 10 2026, Perspective Therapeutics Inc (CATX) has a P/B ratio of 0.86. This indicates that the market values CATX at 0.86 times its book value.
What is the current FCF Yield for Perspective Therapeutics Inc (CATX) as of Jan 10 2026?
As of Jan 10 2026, Perspective Therapeutics Inc (CATX) has a FCF Yield of -51.46%. This means that for every dollar of Perspective Therapeutics Inc’s market capitalization, the company generates -51.46 cents in free cash flow.
What is the current Forward P/E ratio for Perspective Therapeutics Inc (CATX) as of Jan 10 2026?
As of Jan 10 2026, Perspective Therapeutics Inc (CATX) has a Forward P/E ratio of -1.86. This means the market is willing to pay $-1.86 for every dollar of Perspective Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Perspective Therapeutics Inc (CATX) as of Jan 10 2026?
As of Jan 10 2026, Perspective Therapeutics Inc (CATX) has a Forward P/S ratio of 350.46. This means the market is valuing CATX at $350.46 for every dollar of expected revenue over the next 12 months.